surmount-1 tirzepatide non-diabetic obesity weight loss SURMOUNT-1: Adults achieve of 16% or more at 72 weeks with Tirzepatide for the Maintenance of

Why is Trulicity not approved for weight loss

These include: Nausea (affecting 2040% of users, usually improving over time) Vomiting, diarrhoea, and constipation Abdominal pain and bloating Reduced appetite (intended effect, but can be excessive) Less common but more serious adverse effects include pancreatitis (inflammation of the pancreas), gallbladder problems including gallstones, and hypoglycaemia (particularly in people also taking diabetes medications)

A systematic review of 35 prospective cohort studies assessing the association between vitamin B 12 status and cognitive deterioration in older individuals with or without dementia at baseline did not support a relationship between serum vitamin B 12 concentrations and cognitive decline, dementia, or Alzheimers disease (79)

OSA as a Part of Cardiometabolic Health: One Intervention, Multiple Benefits Another forward-looking aspect of treating OSA with drugs like tirzepatide is the opportunity to fold sleep apnea management into a broader cardiometabolic health strategy